Ethical, social and economic issues in familial breast cancer: a compilation of views from the EC biomed II demonstration project by Steel, M et al.
Disease Markers 15 (1999) 125–131
IOS Press
0278-0240/99/$8.00 © 1999 – IOS Press. All rights reserved
125
Michael Steel1,#, Elizabeth Smyth1,
Hans Vasen2, Diana Eccles3, Gareth Evans4,
Pål Møller5, Shirley Hodgson6,
Dominique Stoppa-Lyonnet7, Jenny Chang-
Claude8, Maria Caligo9, Patrick Morrison10
and Neva Haites11
1School of Biology, Division of Medical
Science and Human Biology, University of St
Andrews, Fife KY16 9TS, Scotland, UK
2Foundation for the Detection of Hereditary
Tumours, c/o University Hospital,
Rijnsburgerweg 10, 2333 AA Leiden, The
Netherlands
3CRC Genetic Epidemiology Research
Group, Wessex Regional Genetics Service,
Southampton, SO9 4HA, UK
4Department of Medical Genetics, St Mary’s
Hospital, Hathersage Road, Manchester M13
0JH, UK
5The Norwegian Radium Hospital, N-0310,
Oslo, Norway
6Division of Medical and Molecular
Genetics, Guy’s Hospital, London Bridge,
London SE1 9RT, UK
7Unité de Génétique Oncologique, Institut
Curie, Section Medicale, 26 Rue d’Ulm,
75231 Paris cedex 05, France
8Division of Epidemiology, German Cancer
Research Centre, Im Neuenheimer Feld 280,
D-69120 Heidelberg, Germany
                                                          
#
 Correspondence: Dr. Michael Steel, School of Biology,
Division of Medical Science and Human Biology,
University of St Andrews, Fife KY16 9TS, Scotland, UK
9Institute of Pathology, University of Pisa,
Via Roma 57, 56126, Pisa, Italy
10Department of Medical Genetics, City
Hospital, Belfast BT9 7AB, UK
11Department of Medicine and Therapeutics
(Medical Genetics), Aberdeen University
Medical School, Foresterhill, Aberdeen
AB25 2ZD, Scotland, UK
ABSTRACT: Demand for clinical services for
familial breast cancer is continuing to rise across
Europe.  Service provision is far from uniform and, in
most centres, its evolution has been determined by
local conditions, specifically by local research
interests, rather than by central planning.  However, in
a number of countries there is evidence of progress
towards co-ordinated development and audit of clinics
providing risk assessment, counselling, screening and,
in some cases, prophylactic intervention.  Much
important information should emerge from continued
observation and comparative assessment of these
developments.
In most countries for which relevant data are
available, there is a distinct bias towards higher social
class among those who avail themselves of clinic
facilities (in line with findings from many other
health-promotion initiatives).  This should be
addressed when considering future organisation of
clinical services.
Molecular genetic studies designed to identify the
underlying mutations responsible for familial breast
cancer are not generally regarded as part of the clinical
service and are funded through research grants (if at
all).  Economic considerations suggest that there is a
case for keeping this policy under review.
Familial cancers throw into sharp relief certain ethical
and legal issues that have received much recent
attention from government advisory bodies, patients’
representatives, professional commentators and the
popular media.  Two are of particular importance;
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first, the right to gain access to medical records of
relatives, in order to provide accurate risk assessment
for a given family member, versus the right to privacy
in respect of personal medical information and,
second, the obligation (or otherwise) to inform family
members of their risk status if they have not actively
sought that knowledge.  The legal position seems to
vary from country to country and, in many cases, is
unclear.  In view of pressures to establish uniform
approaches to medical confidentiality across the EC, it
is important to evaluate the experience of participants
in this Demonstration Programme and to apply the
principle of “non-malfeasance” in formulating regu-
lations that should govern future practice in this field.
Data on economic aspects of familial breast cancer are
remarkably sparse and outdated.  As evidence accrues
on the influence of screening and intervention
programmes on morbidity and mortality, there is a
strong case for evaluating the cost-effectiveness of
different models of service provision.
INTRODUCTION
Although the existence of familial forms of
common cancers, including breast, has been
recognised for over a century, the medical
profession, with a few notable exceptions, has
paid little attention to the clinical implications
until the present decade.  Suddenly, heritable
cancer risk has become an issue of concern not
only within the narrow field of clinical genetics
but in the public domain, as demonstrated by the
proliferation of articles in the popular press,
programmes on radio and television and pressure
from families, who believe themselves to be at
increased risk, for access to appropriate
counselling and screening services.
In most countries, health services were ill
prepared to meet the surge in demand.  This
applies to North America [1] as well as to
Europe.  “Cancer Family Clinics” have therefore
evolved, in piecemeal fashion, from a variety of
starting points, often based on research activity in
academic centres [2].  In several instances,
national and regional plans are now being
formulated to extend services to a wider
population [3].  For example, the development of
cancer family clinic networks under the UK
National Health Service followed reports from
advisory committees set up for England and
Wales [4] and, separately, for Scotland [5].
Comparable activity in several other European
countries is recorded in a number of papers
elsewhere in this volume.  A major purpose of
this Demonstration Programme has been to
collate experience from centres that have been
operating under a variety of different
circumstances, to identify potential solutions to
common problems.
ORGANISATION OF CLINICS
Since cancer family clinics must serve multiple
purposes — ascertainment of those at risk, risk
assessment, counselling about screening or
intervention options, organising screening
programmes, offering molecular diagnosis,
identifying and responding to psychological
needs of cancer families, auditing the outcome of
their own activities, educating healthcare profes-
sionals and the public and undertaking research
[2,6–8] — it might seem that they need to be set
up as multi-disciplinary organisations.  The
availability, on a single site, of specialist
geneticists, surgeons/gynaecologists, radiologists
and psychologists, closely associated with a
molecular diagnostic laboratory, certainly
provides all the requirements for an excellent
service.  However that is not always a practical
possibility and it would be counterproductive to
suggest that no service should be introduced until
all these elements are together under one roof.  In
many centres there are separate but well-
established genetics clinics, breast screening
programmes, clinical psychology services and
molecular biology laboratories whose remits can
be extended to meet the needs of cancer families
without necessarily re-housing any of them.
There is, however some danger that the mere
existence of these individual components may be
presumed to constitute an adequate breast cancer
genetics service.  It should therefore be made
clear that special provision must be made for co-
ordination.  For example, if a patient is assessed
in the genetics clinic as requiring regular clinical
and radiological surveillance, then there must be
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a mechanism for ensuring that this will happen
and, further, that the outcome of screening is
recorded along with the genetic findings.  In
other words, someone must have overall
responsibility for keeping track of what is
happening to that patient (and her family) and the
record should be maintained in a manner that will
permit audit of the service as a whole.  In relation
to mammography, there are specific additional
responsibilities — to ensure appropriate quality
control, to retain serial films for comparative
purposes and to regulate radiation exposure [9].
CHARACTERISTICS OF CLINIC
CLIENTELE
One feature that seems to be common to breast
cancer family clinics in several countries is a
strong bias towards higher social class among
their clientele.  This had been noted in seven out
of twelve clinics surveyed: only two believed
there was no such bias in their population while
three could not make an assessment.  In south-
east Scotland the bias takes the form of a
considerable excess of university graduates
(including a substantial proportion of healthcare
professionals) and a significant deficit of the
most deprived group [10] (Figure 1).  While
similar patterns are well recognised in other
health-promotion programmes [11], it does
appear to be more extreme in this particular
setting.  To some extent, this is understandable,
given that, in the early days of the service,
women had to be uncommonly “aware” of the
specific health issue of familial breast cancer in
order to find their way to the clinics.  However, a
survey of European centres within this
Demonstration Programme suggested that there
has been only a slight trend towards levelling-out
across the social spectrum as services have
become better established.  An interesting
Fig. 1.  D
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suggestion, from formal psychological assess-
ment of the Edinburgh clinic population, is that
those classified as “Blunters” on the Miller
behaviour scale (i.e. who tend to cope with issues
by avoidance or denial) seem much less likely to
be referred to the clinic by their family doctor if
they belong to a socially deprived group.  This
may imply that, at present, GP’s are not able to
identify the less articulate subgroup of at-risk
women.
Despite the well-known trend for breast cancer
to be commoner in women of high social class,
the distorted social mix of breast cancer family
clinic patients should be addressed if the service
is to reach all those in need.  Information
campaigns directed both at primary healthcare
workers and at women from lower social groups
may be necessary.  There could be a specific
“outreach” role for genetics nurse specialists and
perhaps some adjustment of clinic times and sites
(e.g. evening clinics in community centres) to
accommodate women in low-status jobs.  This
topic does appear to merit further study, perhaps
evaluating some of the approaches indicated
above.
THE ECONOMICS OF MUTATION
SEARCHING
In most centres, the service element of
molecular laboratory work is confined to
screening individual members of families where
a specific germline mutation has already been
found.  Searching for new mutations is regarded
as a research activity and can be funded only
from competitive grants [3].  As the efficiency of
mutation-detection improves, the case for
regarding it as “pure research” becomes weaker
and the economic argument for allocating some
service resources for this purpose becomes
stronger [12].
A reasonable estimate of the new referral rate
of families at substantially increased genetic risk
of breast cancer is about 450 per year per million
population.  These, in the main, will be women
requiring annual screening between the ages of
35 and 50.  A “steady state” will then be achieved
after 15 years, when 450 women aged 50 will
cease to require screening and another 450
(spanning the full age range) will replace
them.  The total number receiving an annual
clinical examination and mammogram will be
around 6000 and the total annual cost something
over 1 million Euros.  An effective mutation-
detection protocol might lead to some 30% of
these patients being discharged from further
follow-up because they can be shown not to be at
risk [13].  Obviously, the figures presented are
somewhat speculative and depend, to a great
extent, on the population frequency of recurring
founder mutations [12] but it would seem wise to
keep under review the economics of molecular
laboratory input to this area.
MEDICAL INFORMATION: PRIVACY
AND LEGITIMATE ACCESS
In recent years there have been many attempts
to formulate an acceptable ethical and legal
framework that protects the privacy of individual
records yet permits necessary epidemiological
and clinical research [14–23].  These are often
characterised by indecision or vagueness when
addressing specific, real-life situations.  In the
field of genetics there is the special issue of
whether information about heritable factors can
be regarded as the “property” of any one
individual rather than belonging to all who share
the same inheritance.  At one extreme, it might be
suggested that taking a family history in the
clinic infringes the rights of relatives who have
not given explicit permission for their illnesses to
be divulged.  In that case, is it the doctor who
asks the questions or the patient who answers
who is at fault? Of course we descend rapidly
into absurdity in pursuing this argument.
Nevertheless, when assessment of risk and
decisions about management rest on a family’s
medical history, the onus is on the doctor to
ensure that the information on which he/she is
acting is as accurate and complete as possible.
This often requires seeking confirmation of
diagnosis in a relative from hospital records.
In the majority of instances, relatives are
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willing, indeed eager, to authorise access to their
health records and there is no question that the
preferred route to such information is through the
family member who has been referred to the
clinic and who can raise the issue with her
relatives before a formal approach is made for
written consent.  However, problems can arise
when there is little personal contact within a
family or where the family tree is unusually
extensive so that distant relatives whose medical
histories may be relevant, are not known
personally to the proband.  Then questions arise
about the justification or otherwise for taking
steps to verify the medical information.  We may
not know, until the information has been
obtained, whether it falls into the category of
genetic data “jointly owned” by all the family;
yet, particularly in such a sensitive area as
breast/ovarian cancer, to ask a relative — not in
direct contact with the proband and possibly
unaware of any concern about familial cancer —
for access to her medical records, could often
cause unwarranted distress.  Furthermore, the
logistic problems of tracing relatives or their next
of kin before proceeding to verify family
histories provided in the clinic would add
enormously to the workload (and cost) of a
cancer family service.
While the law remains very uncertain in most
European countries, there are pressures to reach a
common policy, one which places a very high
premium on the concept of privacy [21].  As
indicated above, such a policy, if enforced, could
operate to the detriment of good medical practice,
specifically, though not exclusively, in the field
of genetics.  It is worth noting that in existing
legal codes, privacy is never paramount
[17,21,24].  Provision is invariably made for
disclosure of medical information in the interests
of public safety (e.g. in the case of “notifiable”
infections) and, revealingly, to counter fraudulent
claims where healthcare is provided through
private insurance! The public interest might be
better served by an approach to legislation that
deals very severely with abuse of confidential
medical information rather than placing barriers
in the way of accessing that information for
legitimate purposes.  All health care professionals
explicitly accept the duty to respect the
confidentiality of medical information and deal
with sensitive information every day.  Exchange
of data about patients is a common and necessary
part of routine practice in virtually every
speciality and professional standards of
confidentiality are taken for granted in such
exchanges.  There is at least a case for
recognising the legitimacy of this practice in
genetics.  The principle of “non-malfeasance”
would seem to be appropriate, meaning that
individuals should be protected from the harm
that might come from release of their medical
details but there should be no automatic
prohibition of activities which cause no harm
[25].
DUTY OF CARE
There remains the vexed question of “the
cousin in Australia”, subjecting the geneticist to
competing ethical pressures; on the one hand, to
respect the wish for privacy on the part of those
family members with whom the clinic has direct
contact but, on the other, to recognise that more
distant relatives have the right to be advised of
possible genetic risk to themselves.  As evidence
grows for the benefits of early detection (or
prevention) of cancer through recognition of
genetic risk, it becomes increasingly likely that a
relative who has not been advised of her possible
risk status might bring a case for negligence
against a geneticist (or his/her employing
authority) who has known of the existence of that
risk but who has not taken reasonable steps to
warn all potentially affected members of the
family [17,22,25,26].
From the preceding discussion, it should be
clear that unwillingness on the part of the original
patient to share with her family information about
genetic risk is unlikely to be an adequate
defence.  In other words, if risk is recognised and
especially if there are risk-reduction measures
available, then there is a duty to transmit that
information.  But how far does that duty extend?
Does it apply only to those family members
known to the original patient or does the clinic
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need to put in place mechanisms for extending
family trees through access to public records of
births, marriages and deaths — by advertising in
the press or by circulating bulletins to General
Practitioners? Who should bear the cost of these
measures?
There are no simple answers to these questions
but there may be an opportunity now to address
them calmly before we are faced with an actual
case that could set a precedent, exacerbating an
already difficult problem.
COST EFFECTIVENESS
Finally, while the motivation for establishment
of cancer genetics services is not primarily
economic, it is prudent to examine the cost-
effectiveness of any new development in health
care.  The overall costs of breast cancer family
clinics are not very difficult to calculate and can
be modified, for example, by altering the criteria
for eligibility (i.e. the age range of patients and/or
the numbers of affected relatives, their ages of
disease onset and the closeness of the family
relationship).  Screening frequency may also be a
relevant variable and introduction of more
expensive techniques such as MRI could enter
the equation.  Greater use of nurse specialists and
genetics associates may play some part in
containing costs.  The other side of the
calculation — the savings to be made by
prevention or early detection of breast/ovarian
cancer — is much more difficult to work out.
There are surprisingly few data on current costs
of managing advanced breast cancer in young
women.  The two most commonly cited papers
[27,28] predate the development of very
expensive drugs such as the taxanes or modern
aggressive approaches to chemotherapy with
autologous bone marrow reinfusion.  Young
breast cancer patients are the most likely
candidates for these regimes.  Some account
should also be taken of the “social” cost of
prolonged illness and death in young women who
have responsible jobs and/or who are bringing up
young children.  However, we require data of the
type now emerging from this Demonstration
Programme to begin realistic modelling of the
reductions in morbidity and mortality to be
anticipated from cancer family clinics.  Attention
should therefore be given very soon to a thorough
economic appraisal of this development in health
care.
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